

# Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer

Angus G Dalglish, Justin Stebbing, Douglas JA Adamson, Seema Safia Arif, Paolo Bidoli, David Chang, Sue Cheeseman, Robert Diaz-Beveridge, Carlos Fernandez-Martos, Rob Glynne-Jones, Cristina Granetto, Bartomeu Massuti, Karen McAdam, Raymond McDermott, Andrés J Muñoz Martín, Demetris Papamichael, Roberto Pazo-Cid, Jose M Vieitez, Alberto Zaniboni, Kevin J Carroll, Shama Wagle, Andrew Gaya and Satvinder S Mudan

**Correction to:** *British Journal of Cancer* (2016) **115**, 789–796.  
doi:10.1038/bjc.2016.271

Upon publication of the above paper in the *British Journal of Cancer*, the authors identified an error in one of their affiliations.

The authors would like to apologise for this mistake. The correct affiliation for Andrés J Muñoz Martín is 'Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain.'